List view / Grid view

Regs & Legs


Outsourcing in early drug discovery: Evolution and opportunities

26 April 2012 | By Jayshree Mistry, Paul Lloyd, Kevin Oliver and Peter North, GlaxoSmithKline R&D and Duncan Judd, Awridian

This article describes the evolution of outsourcing within early drug discovery at GlaxoSmithKline (GSK), specifically for chemistry services applied to developing a compound from the screening hit through lead optimisation. It will touch on different business models, factors to consider when selecting potential CROs, the benefits of outsourcing and CRO…


9 March 2012 | By Accelrys

Learn more about HEOS® by SCYNEXIS - a SaaS workspace in which multiple, disparate companies, academic collaborators or CROs can exchange scientific data securely and in real-time.

Jentadueto™ tablets, now available in U.S. pharmacies

7 March 2012 | By Eli Lilly and Company

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto™ (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes

30 January 2012 | By Eli Lilly and Company

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…

FDA approves NULOJIX® (belatacept)

16 June 2011 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

Thermo Fisher Scientific helps optimise productivity of bioequivalence studies and regulatory compliance

24 May 2011 | By

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that International Pharmaceutical Research Center (IPRC) has implemented Thermo Scientific Watson LIMS (laboratory information management system) to improve productivity of its Phase I clinical trials unit while enabling compliance with current regulatory requirements.

FDA approves linagliptin tablets for the treatment of type 2 diabetes

3 May 2011 | By OgilvyHealthPR

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…

is it ever right to sue a client?

19 April 2011 | By Jim Kinnier Wilson, Partner, Manches

Imagine that you are part of a small biotech company, BiotechCo, whose business is the development of delivery systems for pharmaceutical products. One of your team, who is in charge of developing sales with a large pharmaceutical company, Pharma Co, came to you three months ago with the possibility of…

PharmaChemical Ireland launch innovation and excellence strategy in New York

16 December 2010 | By Matt Moran, Director, PharmaChemical Ireland

PharmaChemical Ireland published a major strategy document in March 2010. The document, titled, ‘Innovation and Excellence-PharmaChemical Ireland Strategic Plan’ was launched at the Drug Chemical and Allied Technologies (DCAT) meeting at the Waldorf Astoria, New York City on 16 March 2010. The document outlines the industry response to the major…

Send this to a friend